Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Long Term Follow-Up of 103 Untreated Adult Patients with Type 1 Gaucher Disease
Tama Dinur, Ari Zimran, Michal Becker‐Cohen, et al.
Journal of Clinical Medicine (2019) Vol. 8, Iss. 10, pp. 1662-1662
Open Access | Times Cited: 26

Showing 1-25 of 26 citing articles:

Value of Glucosylsphingosine (Lyso-Gb1) as a Biomarker in Gaucher Disease: A Systematic Literature Review
Shoshana Revel‐Vilk, Maria Fuller, Ari Zimran
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 19, pp. 7159-7159
Open Access | Times Cited: 78
Gaucher disease: Basic and translational science needs for more complete therapy and management
Gregory A. Grabowski, Armand H. Matheny Antommaria, Edwin H. Kolodny, et al.
Molecular Genetics and Metabolism (2020) Vol. 132, Iss. 2, pp. 59-75
Open Access | Times Cited: 45
Gaucher Disease Diagnosis Using Lyso-Gb1 on Dry Blood Spot Samples: Time to Change the Paradigm?
Tama Dinur, Peter Bauer, Christian Beetz, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 3, pp. 1627-1627
Open Access | Times Cited: 25
High-Dose Ambroxol Therapy in Type 1 Gaucher Disease Focusing on Patients with Poor Response to Enzyme Replacement Therapy or Substrate Reduction Therapy
Majdolen Istaiti, Dafna Frydman, Tama Dinur, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 7, pp. 6732-6732
Open Access | Times Cited: 11
Never‐Treated, Non Splenectomised Patients With Gaucher Disease (The French GANT Study): The Prospective Follow‐Up
Alberto Nascè, Yann Nguyen, Nadia Belmatoug, et al.
Journal of Inherited Metabolic Disease (2025) Vol. 48, Iss. 2
Closed Access
Gaucher disease and SARS-CoV-2 infection: Emerging management challenges
Pramod K. Mistry, Manisha Balwani, Deborah Barbouth, et al.
Molecular Genetics and Metabolism (2020) Vol. 130, Iss. 3, pp. 164-169
Open Access | Times Cited: 31
Treatment Efficiency in Gaucher Patients Can Reliably Be Monitored by Quantification of Lyso-Gb1 Concentrations in Dried Blood Spots
Claudia Cozma, Paskal Cullufi, Guido Kramp, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 13, pp. 4577-4577
Open Access | Times Cited: 29
Economic burden and health related quality of life of ultra-rare Gaucher disease in China
Xinye Qi, Jiao Xu, Linghan Shan, et al.
Orphanet Journal of Rare Diseases (2021) Vol. 16, Iss. 1
Open Access | Times Cited: 24
Gaucher disease protects against tuberculosis
Jingwen Fan, Victoria L. Hale, Lindsey T. Lelieveld, et al.
Proceedings of the National Academy of Sciences (2023) Vol. 120, Iss. 7
Open Access | Times Cited: 10
The natural history of Gaucher disease type 1 in 31 patients over a median of 15 years: a retrospective study
Siavash Piran, Graeme Nimmo, A. Chaboureau, et al.
Internal Medicine Journal (2024) Vol. 54, Iss. 10, pp. 1661-1668
Open Access | Times Cited: 3
Hematological manifestations and complications of Gaucher disease
Shoshana Revel‐Vilk, Jeff Szer, Ari Zimran
Expert Review of Hematology (2021) Vol. 14, Iss. 4, pp. 347-354
Closed Access | Times Cited: 21
Impact of Long-Term Enzyme Replacement Therapy on Glucosylsphingosine (Lyso-Gb1) Values in Patients with Type 1 Gaucher Disease: Statistical Models for Comparing Three Enzymatic Formulations
Tama Dinur, Ulrike Grittner, Shoshana Revel‐Vilk, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 14, pp. 7699-7699
Open Access | Times Cited: 18
Lysosomal storage disorders identified in adult population from India: Experience of a tertiary genetic centre and review of literature
Jayesh Sheth, Aadhira Nair, Riddhi Bhavsar, et al.
JIMD Reports (2024) Vol. 65, Iss. 2, pp. 85-101
Open Access | Times Cited: 2
Patient reported outcome measures in a large cohort of patients with type 1 Gaucher disease
Tama Dinur, Majdolen Istaiti, Dafna Frydman, et al.
Orphanet Journal of Rare Diseases (2020) Vol. 15, Iss. 1
Open Access | Times Cited: 17
Contribution of Glucosylsphingosine (Lyso-Gb1) to Treatment Decisions in Patients with Gaucher Disease
Tama Dinur, Peter Bauer, Christian Beetz, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 4, pp. 3945-3945
Open Access | Times Cited: 6
Identification of a Reliable Biomarker Profile for the Diagnosis of Gaucher Disease Type 1 Patients Using a Mass Spectrometry-Based Metabolomic Approach
Iskren Menkovic, Michel Boutin, Abdulfatah Alayoubi, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 21, pp. 7869-7869
Open Access | Times Cited: 16
The role of glucosylsphingosine as an early indicator of disease progression in early symptomatic type 1 Gaucher disease
Ashlee R. Stiles, Erin Huggins, Luca Fierro, et al.
Molecular Genetics and Metabolism Reports (2021) Vol. 27, pp. 100729-100729
Open Access | Times Cited: 14
A patient with Gaucher disease and plasma cell dyscrasia: bidirectional impact
Ari Zimran, Rosa Ruchlemer, Shoshana Revel‐Vilk
Hematology (2020) Vol. 2020, Iss. 1, pp. 389-394
Open Access | Times Cited: 10
A Cross-Sectional Retrospective Study of Non-Splenectomized and Never-Treated Patients with Type 1 Gaucher Disease
J. Serratrice, Jérôme Stirnemann, Amina Berrahal, et al.
Journal of Clinical Medicine (2020) Vol. 9, Iss. 8, pp. 2343-2343
Open Access | Times Cited: 8
Dystonia as initial presentation of compound heterozygous GBA2 mutations: Expanding the phenotypic spectrum of SPG46
Katja Kloth, Claudia Cozma, Maxim Bester, et al.
European Journal of Medical Genetics (2020) Vol. 63, Iss. 9, pp. 103992-103992
Closed Access | Times Cited: 7
Causes de décès dans la maladie de Gaucher de type 1
R. Deshayes, Yann Nguyen, J. Stirnemann, et al.
La Revue de Médecine Interne (2024) Vol. 45, pp. A91-A91
Closed Access
The N370S/R496H genotype in type 1 Gaucher disease – Natural history and implications for pre symptomatic diagnosis and counseling
Natasha Zeid, Chanan Stauffer, Amy Yang, et al.
Molecular Genetics and Metabolism Reports (2020) Vol. 22, pp. 100567-100567
Open Access | Times Cited: 3
Alpha-Synuclein mRNA Level Found Dependent on L444P Variant in Carriers and Gaucher Disease Patients on Enzyme Replacement Therapy
Paweł Dubiela, Paulina Szymańska-Rożek, Andrzej Eljaszewicz, et al.
Biomolecules (2023) Vol. 13, Iss. 4, pp. 644-644
Open Access | Times Cited: 1
Glucosylsphingosine (Lyso-Gb1): An Informative Biomarker in the Clinical Monitoring of Patients with Gaucher Disease
Matthew M. Gayed, Seung‐Hye Jung, Erin Huggins, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 23, pp. 14938-14938
Open Access | Times Cited: 2
Gaucher disease: A cause of massive splenomegaly in a 15-year-old black African male
Tanusha Ramdin, Elise Schapkaitz, S Varughese, et al.
South African Medical Journal (2021), pp. 17-20
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top